Vertex Raises Bottom End of 2025 Revenue Guidance Range
Image Source: Vertex Pharma By Brian Nelson, CFA Vertex Pharmaceuticals (VRTX) reported mixed first quarter results on May 5, with revenue and non-GAAP earnings per share coming in lower than forecast, but the company raised the low end of its revenue guidance range for 2025. Total revenue increased 3% compared to the first quarter of 2024 thanks to continued performance of TRIKAFTA/KAFTRIO and an early contribution from the U.S. launch of ALYFTREK. U.S. total revenue increased 9%, while non-U.S. revenue fell 5% due in part to a violation of its intellectual property rights in Russia, of which it notes to be a “limited and isolated matter.” Management had the following to say about the quarter: Vertex delivered a strong start … Read more